Alamar Biosciences has launched the NULISAqpcr AD 5-plex Assay, a Research Use Only (RUO) solution designed to advance blood-based research in Alzheimer’s disease and related neurodegenerative disorders.
The assay enables simultaneous quantitative measurement of five critical biomarkers from a single blood or plasma sample.
The 5-plex panel aligns with Alzheimer’s Association–recommended biomarkers and includes:
Together, these markers provide a comprehensive molecular snapshot of disease biology.
Most current approaches rely on single-plex assays, requiring multiple tests to capture disease complexity. The NULISAqpcr AD 5-plex Assay consolidates this process into one multiplexed workflow, offering:
Its application extends beyond Alzheimer’s to other cognitive and neurodegenerative disorders.
Dr. Yuling Luo, founder, chairman and CEO of Alamar, described the launch as a milestone in precision proteomics.
He emphasized that combining critical protein targets into one assay helps accelerate early detection, screening, and precision diagnosis.
Dr. Steven Williams, chief scientific officer, highlighted the growing role of blood-based biomarkers.
He noted that multiplexed measurement delivers richer biological insight than isolated biomarker testing.
The NULISAqpcr AD 5-plex Assay is available immediately as a service through Alamar’s Technology Access Programme.
Alamar Biosciences is a privately held life sciences company focused on precision proteomics for early disease detection.
Its platform is built on proprietary NULISA technology and the ARGO HT System, designed to overcome sensitivity and scalability limitations of existing proteomic tools.